Cell and Gene Therapies: How is the Market Faring? 
By

By
Cell and gene therapies are a niche segment in the global bio/pharmaceutical market. What are leading products, and what are key developments thus far in 2025? 

Productivity, Wages, and AI: A Plus or Minus?
By

By
A recent PwC analysis examined the impact of productivity, wages, and overall value in industries with strong and limited exposure to AI. What did it find?

Will New Oral GLP-1 Agonists Be the Next Market Shaker?
By

By
The blockbuster success of Novo Nordisk’s Ozempic/Wegovy and Lilly’s Mounjaro/Zepbound, all injectables, have put GLP-1/GIP agonists on the map, but will new oral drugs be a game-changer?

The Push To Onshore US Pharma Manufacturing: What’s on the Table?
By

By
Congress is moving forward with proposed legislation to increase both new and reshored pharma manufacturing in the US. What measures are being considered, and where do they stand?

On the Rise: CDMO/CMO Expansions for Injectables
By

By
Strong growth is projected for the injectables drugs market, and CDMOs/CMOS are expanding sterile manufacturing & fill–finish capacity. Which companies are expanding and who is leading the charge?

Pharma Industry-Specific Tariffs: Industry Weighs In
By

By
The industry has weighed in on the US government’s potential plan to impose tariffs specific to the pharmaceutical industry. Where does the initiative stand, and what is the industry saying?

Headwinds or Tailwinds: Will the Biotech Sector Rebound in 2025?
By

By
Capital flow in the biotech sector has been under pressure with macro factors in the US on tariffs, tax & monetary policy, and drug pricing reforms contributing to uncertainty. But will the tide turn?

New Modalities & More Upsides in the Oncology Drug Market
By

By
New modalities, ADCs and bispecific antibodies, accounted for $18 billion in cancer medicine spending in 2024 and are fast-growing on a pipeline basis. What else stands out in the oncology drug market?

What Makes A Customer of Choice: Are Pharma Companies & Suppliers Aligned? 
By

By
In times of supply-chain uncertainty, a new DCAT Research & Benchmarking report addresses a key question in the pharma customer–supplier relationship: What does it take to become a “Customer of…

Antibody Drug Conjugates: Will the Growth Prospects Continue or Not or is the Shine Off?
By

By
Antibody drug conjugates (ADCs) have been a strong niche in the global oncology drug market. What are the leading commercial ADCs and key pipeline contenders, and will ADCs continue to bode well for CDMOs/CMOs? A look at what lies ahead.